Mice deficient in endothelial NO synthase (eNOS), the key enzyme for NO production in vessels, are characterized by faster erythrocyte clearance, possibly due to enhanced erythrocyte PS exposure and subsequent phagocytosis [170]
Listen to Resiliency Radio episode 281 with Dr
Slower glutathione synthesis : Patients with T2DM also had lower rates of glutathione production
The semaglutide injections are ridiculously easy to do (I was scared at first, but trust me, it's nothing), and my cravings are justgone
What we know: Retatrutide activates GLP-1, GIP, and glucagon receptors simultaneously Phase 2/3 trials show 24-29% weight loss at highest doses Side effects are similar to other incretin medications (mainly GI) It may be particularly effective for liver fat reduction FDA approval is potentially years away What to consider: Approved alternatives (semaglutide, tirzepatide) have established safety profiles "GLP-3" marketing may oversimplify or mislead Investigational drugs carry unknown long-term risks Quality control for compounded versions is variable Clinical trial results don't always translate to real-world outcomes The bigger picture: Retatrutide may represent a genuine advance in obesity treatmentthe data is genuinely impressive
:max_bytes(150000):strip_icc()/WhatstheDifferenceBetweenOzempicWegovyandMounjaro-illo-a8f5a23fe4914586b4488472fe15f112.png)
More recent DSIP and DSIP-analogue research, involving modified compounds designed to behave similarly to DSIP, has explored possible neuroprotective and stroke-recovery roles in animal models, but this work remains preclinical rather than validated through large human therapeutic trials [1112][1819]